Loading
Life sciences · Phase 1/2 Trial
ClinicalTrials.gov · October 30, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Phase 1/2 Trial.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07889232). This is a study registration, not published results. Lead sponsor: VA Office of Research and Development. Recruitment status: NOT_YET_RECRUITING. Phase: PHASE1, PHASE2. Study type: INTERVENTIONAL. Enrollment: 43 participants (ESTIMATED). Conditions: Metastatic Non-Small Cell Lung Cancer, Cancer-Associated Weight Loss, Elevated Inflammatory Markers. Interventions: DRUG: Tocilizumab; DRUG: Pembrolizumab; DRUG: Platinum-Doublet Chemotherapy. Primary outcome measures: Safety of adding Tocilizumab to Standard of Care Immunotherapy , From Day 1 of treatment through completion of Cycle 4 (approximately 12 weeks); Progression-Free Survival Rate , 6 months after after initiation of study treatment; Feasibility of Treatment Completion , From Day 1 of treatment through completion of Cycle 4 (approximately 12 weeks). Brief summary: This is a Phase 1b/2, multi-site, single-arm, open-label, non-randomized study looking at whether adding tocilizumab to standard treatment for metastatic Non-Small Cell Lung Cancer (NSCLC) is safe, possible, and effective. The study includes people with metastatic NSCLC, that is lung cancer that has spread, who have experienced significant loss of weight or muscle mass.